In conclusion, our findings and these studies suggest that targeting PIPKIγ-exosomal PD-L1 axis might provide a new therapeutic target for CRC patients who are not sensitive to or resistant to oxaliplatin chemotherapy. This evidence concerns the gene CD274 and colorectal carcinoma.